MIST vs. CARA, UNCY, RGLS, LEXX, KRRO, OCUP, DARE, CLRB, GYRE, and CLNN
Should you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Cara Therapeutics (CARA), Unicycive Therapeutics (UNCY), Regulus Therapeutics (RGLS), Lexaria Bioscience (LEXX), Korro Bio (KRRO), Ocuphire Pharma (OCUP), Daré Bioscience (DARE), Cellectar Biosciences (CLRB), Gyre Therapeutics (GYRE), and Clene (CLNN). These companies are all part of the "pharmaceutical preparations" industry.
Milestone Pharmaceuticals (NASDAQ:MIST) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.
86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are held by institutional investors. 10.4% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 4.2% of Cara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Milestone Pharmaceuticals presently has a consensus target price of $11.20, indicating a potential upside of 525.70%. Cara Therapeutics has a consensus target price of $9.75, indicating a potential upside of 971.43%. Given Cara Therapeutics' higher possible upside, analysts plainly believe Cara Therapeutics is more favorable than Milestone Pharmaceuticals.
Milestone Pharmaceuticals has a net margin of 0.00% compared to Cara Therapeutics' net margin of -565.21%. Cara Therapeutics' return on equity of -122.10% beat Milestone Pharmaceuticals' return on equity.
Milestone Pharmaceuticals has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
In the previous week, Milestone Pharmaceuticals had 3 more articles in the media than Cara Therapeutics. MarketBeat recorded 7 mentions for Milestone Pharmaceuticals and 4 mentions for Cara Therapeutics. Cara Therapeutics' average media sentiment score of 0.59 beat Milestone Pharmaceuticals' score of 0.46 indicating that Cara Therapeutics is being referred to more favorably in the news media.
Milestone Pharmaceuticals has higher earnings, but lower revenue than Cara Therapeutics. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cara Therapeutics received 588 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. Likewise, 74.92% of users gave Cara Therapeutics an outperform vote while only 67.57% of users gave Milestone Pharmaceuticals an outperform vote.
Summary
Milestone Pharmaceuticals beats Cara Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Milestone Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Milestone Pharmaceuticals Competitors List
Related Companies and Tools